Company intelligence / Profile preview

Chengdu Evergreen Pharmaceutical

Ownership: Private
Development stage: Commercial

Overview

Chengdu Evergreen Pharmaceutical is a Chinese pharmaceutical manufacturer with a portfolio of approved small molecule drugs targeting common indications such as fever, infections (including tuberculosis), and acute ischemic stroke. The company appears to focus on manufacturing and distributing established pharmaceuticals rather than developing novel therapeutics or proprietary platforms. There is no indication that it operates at the cutting edge of biotech innovation.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Small moleculesAntibiotics and other traditional pharmaceuticals
Industry: Biotech

Drug pipeline

3 assets

Rykindo

Commercial

Indications: Central nervous system disorders

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Chengdu Evergreen Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Evergreen Pharmaceutical.

Explore the full profile